FAPI vs FDG — When the Newer Tracer Finds More

Which tracer is appropriate is your oncologist's decision, not something to request directly from the imaging centre. The right choice depends on your cancer type, what the scan is meant to answer, and what your team has already seen. FAPI is most likely to add useful information if your cancer is one known to have low FDG uptake or high background — such as gastric, pancreatic or liver cancer. If your FDG scan came back negative but your team still suspects residual disease, it is entirely reasonable to ask whether FAPI would give a clearer picture.

FAPI tracers are used at specialist centres in India and fall under CDSCO's oversight of radiopharmaceuticals. Their use is largely investigational for most cancer types — meaning the evidence is promising but has not yet been formalised into standard national guidelines. CION coordinates FAPI scans through partner imaging centres. Your oncologist can confirm whether FAPI is being used in a routine or research context for your specific situation.

Not for most cancers. FDG remains the standard tracer across the majority of cancer types because decades of evidence support its use in NCCN, ESMO and ASCO guidelines. FAPI is complementary — it adds information in specific situations where FDG is limited, particularly in the liver, stomach, peritoneum and bile ducts. For most patients, FDG is still the right starting point, and FAPI is considered when FDG has known limitations for that cancer type.

Each tracer targets a different biological process. F-DOPA targets dopamine metabolism and is used primarily for neuroendocrine tumours, certain brain tumours and some head and neck cancers. FAPI targets tumour stroma and is most useful in gastrointestinal and peritoneal cancers. They are not interchangeable — the right tracer depends on your cancer type and what your team is trying to detect. In some cases, two tracers may be used at different points to answer different questions.

Coverage varies by insurer and policy. Because FAPI is investigational for most indications, some insurers classify it as experimental and may not cover it under standard health plans. The indicative cost at CION partner imaging centres is ₹23,999 as of 2026. It is worth checking with your insurer before the scan is booked — your team can help with documentation if pre-authorisation is required.

Yes. FAPI PET scans are coordinated through CION's partner imaging centres. Your oncologist at CION will advise whether FAPI is appropriate for your case and refer you to the right centre. CION does not administer FAPI-based therapy — if your team is discussing FAPI as a treatment rather than a diagnostic scan, that would be at a specialist centre. This page covers FAPI as an imaging tracer only.